Novartis' psoriasis rivals tout impressive data with next-gen treatments

Novartis ($NVS) became the first to win approval among a scrum of drugmakers with new antibody treatments for autoimmune disease, but its rivals are bounding toward the FDA with positive data of their own. At the annual American Academy of Dermatology meeting, Boehringer Ingelheim unveiled promising data on its injected treatment, while Pfizer ($PFE) heralded psoriasis results with its autoimmune drug Xeljanz. Each hopes to outpace Novartis' recently approved Cosentyx and contend with candidates from Eli Lilly ($LLY), Merck ($MRK), Johnson & Johnson ($JNJ), and partners Amgen ($AMGN) and AstraZeneca ($AZN). Story

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.